DOJ: CVS Settles for $315 Million Over Unlawful Opioid Prescriptions and False Claims

What this means for your practice

This significant settlement sends a clear message to all healthcare entities, from telehealth providers and medspas to dental and chiropractic offices, about the critical importance of robust compliance programs, especially concerning controlled substances. While directly involving a pharmacy chain, the allegations highlight risks relevant to prescribers: ensuring prescriptions have a legitimate medical purpose, identifying and responding to 'red flags' in prescribing patterns (e.g., early refills, dangerous combinations, 'pill mill' prescribers), and maintaining proper documentation. Practices must understand their role in the chain of care, as regulatory scrutiny extends beyond direct dispensing. The focus on corporate-imposed performance metrics and staffing policies also underscores the need for healthcare businesses to ensure that operational decisions do not compromise patient safety or compliance with legal obligations. Implementing proactive monitoring and evaluation processes, similar to those mandated for CVS, can serve as a valuable model for any practice handling controlled substances or billing federal programs.

HONOLULU, HI – The U.S. Department of Justice (DOJ) has announced that CVS Pharmacy Inc. and its related corporate entities (collectively, CVS) have agreed to pay $315 million to resolve allegations of illegally filling opioid prescriptions and submitting false claims to federal healthcare programs. The settlement addresses claims that, from October 17, 2013, through December 2, 2025, CVS violated the Controlled Substances Act (CSA) by dispensing unlawful prescriptions for opioids and other controlled substances, and subsequently violated the False Claims Act (FCA) by seeking reimbursement for many of these invalid prescriptions from Medicare and other federal programs.

Allegations of Unlawful Dispensing and Corporate Failures

The government's complaint, filed on December 13, 2024, in the U.S. District Court for the District of Rhode Island, alleged that CVS knowingly filled prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, or were not issued in the usual course of professional practice. Specific concerns included:

• Dangerous and Excessive Quantities: Dispensing high volumes of opioids.
• Early Refills: Filling opioid prescriptions too early.
• "Trinity" Prescriptions: Dispensing the dangerous combination of an opioid, a benzodiazepine, and a muscle relaxant.
• "Pill Mill" Prescribers: Filling prescriptions from prescribers known to issue large numbers of controlled substance prescriptions without medical purpose.
• Red Flags: Pharmacists allegedly filled these prescriptions despite clear warning signs indicating a high likelihood that they lacked legitimate medical purpose.

The DOJ further alleged that CVS's violations were exacerbated by corporate-imposed performance metrics, incentive compensation, and staffing policies that prioritized corporate profits over patient safety. It was claimed that CVS failed to employ enough pharmacists to meet its legal obligations and corporate metrics, and that its policies prevented pharmacists from sharing information about problematic prescribers with one another.

Enforcement and Remedial Measures

United States Attorney Ken Sorenson emphasized the commitment to protecting patients and the integrity of federal healthcare programs, stating, "This litigation and resulting settlement demonstrate our solemn commitment to protect patients in our community and the integrity of our federal healthcare programs. We all suffer and pay the cost when large scale fraud infects the claim and payment process as happened here." Associate Attorney General Stanley E. Woodward Jr. added, "Not only does this settlement hold bad actors accountable for their fraudulent activities, but Americans are safer because of it." Assistant Attorney General Brett A. Shumate highlighted the forward-looking aspect of the agreement, stating, "The remedial measures in this agreement — including proactive monitoring of opioid prescribing patterns — will provide critical protections for patients and federal healthcare programs."

In addition to the $315 million monetary payment, CVS has entered into a memorandum of agreement with the DEA to address its future obligations in dispensing controlled substances. This agreement mandates several key safeguards:

• Employee and Public Hotline: Establishing a dedicated hotline for reporting suspected illegal dispensing of controlled substances.
• Proactive Monitoring: Implementing systems to proactively monitor the dispensing patterns of its pharmacies to identify and address potentially illegal dispensing.
• Prescriber Evaluation: Establishing a process to evaluate prescribers suspected of illegal prescribing activities.

DEA Assistant Administrator Cheri Oz affirmed the DEA's commitment to public health, stating, "DEA is unwavering in its commitment to protect public health and ensuring pharmacies adhere to the highest standards of responsible dispensing. We will continue to work closely with law enforcement, regulatory agencies."

First Assistant U.S. Attorney Charles C. Calenda for the District of Rhode Island underscored the importance of effective compliance systems for pharmacies, noting that the settlement "demonstrates the importance of those obligations and the consequences of failing to implement safeguards designed to prevent the improper dispensing of controlled substances."

Key Facts

Frequently Asked Questions

What was CVS accused of in this settlement?

CVS was accused of illegally filling prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act, and then submitting false claims for payment for those invalid prescriptions to Medicare and other federal healthcare programs, violating the False Claims Act.

What types of unlawful prescriptions were highlighted in the allegations?

The allegations included dispensing dangerous and excessive quantities of opioids, prescriptions filled too early, 'trinity' prescriptions (a combination of an opioid, a benzodiazepine, and a muscle relaxant), and prescriptions from 'pill mill' prescribers, all allegedly filled despite clear red flags.

What corporate issues did the DOJ cite regarding CVS?

The DOJ alleged that CVS's violations stemmed from corporate-imposed performance metrics, incentive compensation, and staffing policies that prioritized corporate profits over patient safety, and policies that prevented pharmacists from warning each other about problematic prescribers.

What new safeguards will CVS implement as part of the settlement?

As part of a memorandum of agreement with the DEA, CVS will establish a hotline for reporting suspected illegal dispensing, proactively monitor its pharmacies' dispensing patterns, and create a process to evaluate prescribers suspected of illegal prescribing.

Which federal laws were central to these allegations?

The allegations centered on violations of the Controlled Substances Act (CSA) and the False Claims Act (FCA).

Source: DOJ — CVS Agrees to Pay $315M for Illegally Filling Unlawful Opioid Prescriptions and for Submitting False Claims to the Federal Government · Thu, 15 Oct 2026 12:00:00 +0000